In the chemical industry and particularly in the pharmaceutical industry, separation, purification and refining processes have always had a very important position. Synthesis and natural processes at best seldom deliver the pure required product.
The current situation of the pharmaceutical industry in Germany
In the chemical industry and particularly in the pharmaceutical industry, separation, purification and refining processes have always had a very important position. Synthesis and natural processes at best seldom deliver the pure required product.
The quality requirements and expected efficiency of the pharmaceutical final product have risen drastically in the last few years. This development has been initiated and imposed f rom va rious diffe rent view p o i n t s : i n c reased know l e d ge, market demands etc. Coming from this angle, only a few examples will be discussed. It should be stressed that these examples should not be seen as representative of all purification problems, in any way.
In comparison to the eighties, the latest scientific knowledge about metabolic and toxic interaction, as well as the b i o -ava i l ability of a pharmaceutical active substance have led to greatly changed assessment behaviour. This changed assessment behaviour was not altogether caused by the enormous increase in the performance capability of the analytical procedure, as is so often believed. A variety of different i n fluences and fa c t o rs have helped to cre ate the curre n t assessment scenario.
Nowadays when considering the assessment and classification of ecological and economical interaction -chemists are operating at a very different environment than they were in the past decades.
In the past decades we have witnessed a restructuration and partly a new orientation of the world markets which have even intensified after the resolution of the East/West economic bl o cks wh i ch we re prev i o u s ly at logge r-h e a d s . This generally positive trend has also caused fundamental changes in the West European market situation.
The demand for products at higher and higher degrees of purity and the greater difficulty of the purification problems encountered (such as the resolution of optical isomers) is more and more fo rcing the pharmaceutical industry to use Preparative High Pe r formance Liquid Chromatography (PHPLC). The present contribution discusses briefly the situation of the pharmaceutical industry today and its ch a l e n ge s . With practical examples, it illustrates how PHPLC can compete efficiently with other purification p rocesses like recrystallisation and presents some applications. Examples are also given to illustrate various techniques to make the chromatographic process more rugged and stable.
In the chemical industry, as well as in one of its major sections -the pharmaceutical industry-, a fiercely competitive situation has developed between the European states and the fo rmer COMECON states. A dditional competitors have entered the scene, such as the People's Republic of China, South Ko re a , and others. To an increasing degre e, t h e s e states are taking over as low wage countries which can supply the world market with basic chemicals. As far as the pharmaceutical field is concerned, China can be considered as an example.
The Chinese pharmaceutical industry is pressing in on the bulk goods market very strongly, for example with respect to the most important steroid basic compounds. The situation is such today that marketing experts are of the opinion that in a few years China will become the major bulk steroid manufacturer.
This future market scenario clearly shows that the highly industrialised European countries and especially Germany, in the not too distant future will probably not be the production place for such products. It will become necessary that the German pharmaceutical industry, and more ge n e ra l ly speaking the European pharmaceutical industry, s t a rts devoting itself to high-tech products at a considerably higher extent than before.
The most interesting combination from an economic point of view is a high-tech product with a high added value. On the other hand, high-tech products are R&D intensive, which also means capital intensive. Vice-versa, it means that the high capital expenditure for R&D must not be completely passed into the production of a high-tech product. The product has to be marketable from the point of view of performance and price formation.
Performance requirements in the pharmaceutical industry
The required product purity of >99% is, as a rule, the standard today. However, it can be observed that the trend is moving towards an even higher purity. In this respect, it is important to keep in mind the following points:
• The structure and toxicological behaviour of the impurities must be known. It means that all impurities should be identified.
• If there are unknown impuri t i e s p re s e n t , t h ey are not allowed to be at a level higher than 0.1%. In the near future, a lowering of this limit value to 0.05%, or even less, is expected. The admissible total amount of impurities, at a value of approximatively 0.5%, is discussed in a "relatively vague" way.
However, there are exceptions to these rules. For example, compounds which are suspected of having mutagenic or carcinogenic effects, have no limit value. This means that they have to lie below the limit of detection.
There are also more "generous" exceptions, however. For ex a m p l e, for compounds wh i ch are analogue to the end product, if they are proven toxicologically harmless, higher concentrations are acceptable. Such cases, however, must be regarded as exceptions.
The testing and admission regulations of the national and European admission authorities demand, besides the many other inve s t i gat i o n s , long term stability tests e. g. , with a product that shows a fingerprint as it is described in the submission file. If this fingerprint changes in the future production phase, then follow-up investigations will be necessary. In the worst case, even new toxicological tests and new long term stabilities will be required. For a long term stability test, one should consider 1.5 to 2 years of labour and i nve s t i gations. This situation fo rces the pharm a c e u t i c a l industry to constantly produce the product quality that has previously been defined in the Drug Master Files (DMF). This is often not so easy to achieve and can be illustrated by the following "everyday" situation.
Consider a final compound wh i ch is obtained after a rather large number of synthesis steps. It can happen that, for some reasons, the synthesis route deviates from what it should norm a l ly be. Eve ry chemist in a pharm a c e u t i c a l world knows at least 99 reasons why such a deviation from the plan could come up. Assume, for instance, that the cooling system of the reactor does not perfo rm as ex p e c t e d. Despite the most modern tech n o l ogy and control of the whole chemical reaction through a process control system, it still is not successful in arresting the reaction, at this quality determined stage, at the intended temperat u re leve l . There is not sufficient cooling energy available and the reactor runs off at -5°C instead of the desired -15° C . Consequently, one of the side reactions runs more extens ive ly than intended; and the corresponding by -p ro d u c twhich is present at 1.5% to 2% with a normal reaction runis now present at 10%. The reaction now not only generated the final product but has also created a problem! In the pharmaceutical industry, recrystallisation is one of the main puri fi c ation methods. In the present situat i o n , assume that the manufacturing process stipulates a recrystallisation step. This recrystallisation will very likely not be successful because of the clearly too high level of the relevant by-compound: the specifications state a limit value of 0.2% and the actual value lies at 1.1%.
A ny modifi c ation of the re c ry s t a l l i s ation method -e. g. other solvents-is not possible. For regulatory reasons any kind of deviation from the manufacturing regulations submitted to the authorities is forbidden.
The company chemist who is responsible in such a situation, uses the only legal means possible: he approves the repetition of the already planned, registered and approved recrystallisation; but the recrystallisation has to be done two times more in order to prevent concentration values falling below the specification limits.
The number of recrystallisation steps is then three instead of the predicted one. The yield loss is about 35%. Let us now assume that the product is worth 20 000 DM/kg and the standard batch size is 200 kg. It is simple to calculate what the losses are big. This situation is not an unusual case. It occurs in all pharmaceutical companies in Europe and the USA that the author has had an opportunity to visit.
At Schering, one has learned from the situation fictively p o rt rayed here (but also based on a real example) and PHPLC (Prep a rat ive High Pe r fo rmance Prep a rat ive C h ro m at ograp hy) has replaced cry s t a l l i s ation (in some As mentioned before, when considerably more high-tech products than before we dealt with, then completely different situations (as far as purification processes are concerned) have to be faced. At Schering, as in other pharmaceutical companies where the same situation can be observed, there a re high tech products on-line and in the R&D pipeline. Most of these products have high purification requirements because of the more complex and more demanding chemistry involved. These higher purification requirements have frequently arisen because in those cases the classical purific ation methods not only had a wo rse success rate bu t showed often no success whatsoever.
Other issues must also be kept in mind. For instance, the FDA has announced that a racemic substance will no longer be accepted in the admittance test procedure for drugs in the near future. As yet, the FDA has only accepted the clinical and toxicological investigations and the later marketing of racemic compounds. In the debate regarding racemic mixtures versus optically pure compounds, the drug Contergan ® often crops up as an example. The first real sleeping drug that led to the terrible, notorious foetal deformities, was a ra c e m at e. The Plus-fo rm had safe sleep-inducing effe c t s whereas the Minus-form caused deformities in the foetus. According to today's knowledge in the field, the opinion is that one can test and assess the effects of a racemate very well. However, the FDA regulations, as well as the National and the European authorities (which are becoming more and more comparable to the USA standards), set the law in the pharmaceutical industry. That means, in other words, that the separation of optical isomers will take a substantially more significant role in separation techniques. Chiral phases and SMB (Simulated Moving Bed) are key words in this field.
Case studies of chromatographic separation processes

Crystallisation versus PHPLC
It is clear that an efficient, economical as well as simple crystallisation methods would hardly prompt the demand for a ny ch a n ge to an altern at ive sep a ration tech n o l ogy. However, our experience has told us that many crystallisation processes are far more complex than they initially appear. In these very cases, PHPLC can be an alternative. One of our current separation problems can probably illustrate this.
This product has alre a dy been in production for many years. The combination of crude materials and the special properties of the by-compounds frequently cause problems, however. In order to guarantee good and stabilised quality of the final product, three purification stages were necessary. First, a basic pre-purification using gravity column was carried out. It was followed by two crystallisation steps. The average result of these operations are shown below. A closer examination of the results suggests the following comments:
• the purity is significantly increased by using PHPLC (limitation of specification > 98%),
• the recovery ratio is considerably higher,
• the production costs is higher (about 59%), taking into consideration the throughput.
However, if one considers the value of the product (about 20 000 DM/kg) and the recovery ratio, PHPLC becomes to be more economical than crystallisation, as shown below. The savings occur as follows:
• the recovery ratio of the crystallisation process is 78% at the maximum,
• the recovery ratio of the PHPLC process is 95% in the worst case .
The difference in recovery ratio is then at least 17%. For one kilogram of product processed, this represents a saving of about 3 400 DM.
Although the PHPLC method is 292 DM/kg more expensive than the established crystallisation process, it produces 0.170 kg more product per kilogram processed. The corresponding cost saving is then 3 108 DM /kg.
Increasing separation performance by using recycling technology
The following example illustrates a demanding separation problem: the separation of 2 stereoisomers. For this separation, a maximum separation performance of the chromatographic bed is needed. I f, as in the sep a ration pro blem discussed befo re, t h e d e s i red degree of puri fi c ation perfo rmance has not been achieved despite the use of high performance material and the very critical assessment of the packing quality; it is then often possible to use the re cy cling ap p ro a ch. With this approach, it is not the recycling of crude material but rather the re-injection of a peak (or peak cut) which is made. In order to be prompted to do this, however, the design of the start-chromatograms has to be developed accordingly.
This re cy cling technique is illustrated in the ch romatogram in figure 1.
Increasing the loading capabilities by peak shaving
In preparative chromatography in general and in production ch ro m at ograp hy in part i c u l a r, economical considerat i o n s dictate to depart from the so-called "baseline resolution" so i m p o rtant in analytical HPLC. In order to signifi c a n t ly increase the throughput per cycle, the chromatographic system is heavily overloaded and the peaks overlap more or less. By targeted peak splitting (that means ex t racting a multitude of components from the peak profile) and following individual fractions analysis, the exact individual peak profiles can be determined. On the basis of this information the exact fraction cut can be carried out. An example is shown in figure 2.
Loading and throughput increasing using PAU (Pre Adsorption Unit) and the subsequent interlocking mode
It is often the case that the crude material to be purified contains an extremely large amount of by-compounds. This, as a rule, and apart from numerous other things, leads to two major problems:
• Upon increasing number of crude injections, s o -c a l l e d "residents" which cannot be removed with the eluent used for the separation accumulate in the chromatographic column. It is often the case that such by-compounds cannot be completely re m oved by using pre -c o l u m n s . Consequently, the are chances that the purification column gets slowly fouled, with adverse effects on its separation power. It may become impossible to use the column in a permanent operation.
• If the amount of by-products is too high, then the chromatography column is impeded with an unnecessary load of material, along with concomitant losses of separation performance.
With the help of a kind of pre-adsorption process (PAU, PreAdsorption Unit), it is often relatively simple to remove one or several by-compounds -or at least to reduce their amount quite drastically. Such PAUs should not be considered as a pre-columns.
The production rate rises by the amount of undesire d material which is removed by pre-adsorption. When the PAU c o n c ept is applied to the previous example the fo l l ow i n g results are obtained.
PAU data (related to given example).
Unit Throughput (1) Production rate (2) It is important to point out that the figures given in the previous table are not the result of calculations, but rather the nu m b e rs obtained in practice (with a 300 mm and a 50 mm internal diameter columns) and ex t rap o l ated to a PHPLC system equipped with a column of 800 mm internal diameter.
The effect of PAU treatment is shown in figures 3 and 4 for two consecutive injections of crude material. Figure 3 shows the chromatogram of the crude before PAU treatment, and figure 4 after PAU treatment. Through this technique, m o re " e m p t y " space is produced between the two ch romatograms. This space can be used efficiently for overlapping injections: the next injection is made before the previous one is completely eluted (overlapping mode, see Fig. 5 ). This procedure reduces the effective duration of a run, with concomitant increase in the production rate and decrease in solvent consumption and purification cost.
Shortening the cycle duration and increasing the life of a PHPLC packing material by implementation of a back-flush step
As has alre a dy been mentioned in some of the prev i o u s examples, the crude material to be purified by PHPLC often contains undesirable products which, under the chromatographic conditions chosen for the puri fi c at i o n , elute ve ry 
Dossier
Preparative Chromatography s l ow ly or not at all. This undesirable mat e rial can be by -c o m p o u n d s , excesses of re agents or the re s p e c t ive p roducts can be the remaining auxiliary mat e rials. Th e s e materials can originate from the reaction itself or from the subsequent processing.
In the process chromatography requirements list, alongside the main target of purity and shortest possible labour time, also stands the longest possible life-time of the chromatographic bed. This is a very important point, and not only for economical reasons. That is why "residents" should be eliminat e d. The possibilities of pre -p u ri fi c ation of the crude material previously mentioned (pre-columns and PAU) are not completely effective in every case. This is r egrettable because one can observe situations in wh i ch " re s i d e n t s " , even present in very small amounts, will cause a collapse in a chromatographic bed.
The most extreme case we encountered was with a column of 300 mm internal diameter and 25 cm length packed with 11.6 kg of silica. The presence of 1.1 g only of "residents" accumulated over 50 cycles caused an extreme pressure increase and a drastic decrease of selectivity. The 1.1 g amount of "residents" only penetrated the bed about 0.5 cm, corresponding to a contamination of the bed of about 2% of its length (basically, the "residents" were tr apped at the column inlet). This small contamination was sufficient, however, to render the column almost useless. Frequently, the implementation of a back-flush step can eliminate this very unpleasant situation.
Performance requirements
The synthesis, often via a large number of steps, does not always lead to a pure end-product. This predicament calls for the application of more or less (and more than less, as a ge n e ral rule!) costly puri fi c ation operations. Costly is equal to cost intensive.
The purification step is quite often the most costly step in the production of a pharmaceutical product. Accordingly, it is desirable to reduce as much as possible the purification costs. This should be the short and medium term targets for the future.
The performance requirements in separation technology in the area of product re fining unfo rt u n at e ly cannot be defined with only a few comprehensible figures, values and curves.
H oweve r, the afo re-mentioned pro c e s s e s , needs and scenes cre ate just from themselve s , a re q u i rement pro fi l e manifested in the points emphasised below:
• the highest possible degree of purity (namely the highest purity the product of interest demands).
• the highest possible stability of the sep a ration pro c e s s . This means absolute stability and rep roducibility ove r several purification cycles. From today's point of view, this does not mean 40 or 50 cy cl e s , but rather 1000 cycles.
• the highest possible economy of sep a ration pro c e s s e s which has a measured balance of the basic points mentioned before.
• the solvents and auxiliary materials used in the separation process must comply with today's environmental policies. When this is not the case, for instance if methylene-chloride has to be used, then additional equipment is required. In order to attain the current environmental demands, it is necessary to acquire special performances and technical installations. This all adds up to a considerable cost burden.
Pe r h aps initially these 4 points, wh i ch only serve to d e s c ribe the main pro blem area -special ap p l i c at i o n s demand additional focus points -seem to look like the quadrat u re of a circl e. Established sep a ration pro c e s s e s , s h ow that these problem areas can be resolved.
Separation technology, theory and modelling
For chromatographic separations of substances, the age of ch ro m at ograp hy was initiated by Michail T swett in 1905 (Fig. 6 ), apart from a few side issues occurring at certain points in the 18 th and 19 th centuries. 1905 can be seen as the starting point of chromatography.
Until the late 60s, these developments we re conducted nearly exclusively from empirical data (in very few cases s c i e n t i fi c a l ly theoretical) wh i ch even by today 's standard s was really quite revolutionary.
In the ensuing period of radical ch a n ge, t h e o ries and models were initiated and the foundations for the current period were established. This development of the last 2 decades is due to the work of individual people and groups at colleges and universities, and in the industry as well. Some really pioneering work was ach i eved by this circle within this period of time. However as mentioned before, it was exclusively due to scientific commitment as well as scientific and economic influenced commitment, of those in industry. This led to formation of isolated solutions.
As a rule, universities and colleges lack the financial basis to enable them to work on complex and cost intensive projects.
In wide areas of industry, product purification and also ch ro m at ographical processes are considered part of the whole procedure. Thus, they are incorporated into the comp a ny 's trade secrets. A ny va l u able know -h ow is there fo re obviously not accessible to the public.
The fi rst cautious trend towa rds ch a n ge, s t a rted at PREP'90 where a few colleagues from the industrial sector introduced their work for the first time. In the course of the last 5 years the trend has strengthened so that today a more balanced relation of representatives from industry and universities can be seen at international conferences.
Nevertheless this does not reflect the degree of co-operation. Even today common projects, research etc., bear the traits of only individual efforts.
In order that we can resolve these very complex, fundamental tasks that lie befo re us, the co-operation betwe e n industry and institutions of higher education must be placed on a wider basis.
Stationary phases
The following points should be kept in mind:
• Economic PHPLC sep a rations need high selectiv i t i e s , high loading factors and long life-time of the chromatographic bed. The ch ro m at ographer incre a s i n g ly needs high perfo rmance packing mat e ri a l s , p a rt i c u l a rly wh e n the pressure exerted by process cost increases more and more. The trend is already underway, and in the last 4-5 years, it has been seen that the demand for media corresponding to this criteria has enormously increased. Some manufacturers of separation media have recognised this demand and reacted accordingly. However, from the point of view of the user, one can regret that, at the moment, the number of such manufacturers is still very small.
• For specific processes and for certain thro u g h p u t amounts, tailor-made media will make sense in the future.
• Chiral separations are becoming more and more important at the production scale, for reasons discussed before. S ep a ration media must be manu fa c t u red and marke t e d considerably cheaper in the future than they are today. Also, these materials must become significantly more stable. As an example, one can just mention the "bleeding" effect of many chiral phases.
• The further development of media based on poly m e rs (and possibly also ze o lythes) has not suffi c i e n t ly been recognised as of today.
• This list only add resses some issues and, in no way, should be seen as complete.
Equipment technology/Sytems engineering
As alre a dy discussed, the purity re q u i rements re l ated to p h a rmaceutical drugs result in the fact that PHPLC is employed in many important product classes as purification technology. Thus, for e.g. steroids, diagnostics, ß-carbolines, prostanes are purified by chromatography at industrial scale, as well as proteins and peptides.
